192 related articles for article (PubMed ID: 37519697)
1. Clinical and humoral immune response characterization of SARS-CoV-2 Omicron BA.2.38 infection in pediatric patients.
Liu Y; Zhao L; Wang L; Li Y; Wang L; Yu B; Hu D; Weng H; Guo J; Yang J; Yang J; Yu X
Heliyon; 2023 Jul; 9(7):e18093. PubMed ID: 37519697
[TBL] [Abstract][Full Text] [Related]
2. Omicron BA.1-specific T-cell responses in adults vaccinated with CoronaVac or BNT162b2 in Hong Kong: an observational cohort study.
Mok CKP; Chen C; Zhao S; Sun Y; Yiu K; Chan TO; Lai HL; Lai KC; Lau KM; Ling KC; Chan KKP; Ng SS; Ko FW; Peiris M; Hui DS
Lancet Microbe; 2023 Jun; 4(6):e418-e430. PubMed ID: 37086735
[TBL] [Abstract][Full Text] [Related]
3. CoronaVac and BBIBP-CorV vaccines against SARS-CoV-2 during predominant circulation of Omicron BA.5.2 and BF.7 in China, a retrospective cohort study.
Hu Z; Jin Z; Zhou M; Zhang C; Bao Y; Gao X; Wang G
J Med Virol; 2023 Oct; 95(10):e29143. PubMed ID: 37814963
[TBL] [Abstract][Full Text] [Related]
4. Neutralization sensitivity, fusogenicity, and infectivity of Omicron subvariants.
Wang XJ; Yao L; Zhang HY; Zhu KL; Zhao J; Zhan BD; Li YK; He XJ; Huang C; Wang ZY; Jiang MD; Yang P; Yang Y; Wang GL; Wang SQ; Dai EH; Gao HX; Ma MJ
Genome Med; 2022 Dec; 14(1):146. PubMed ID: 36581867
[TBL] [Abstract][Full Text] [Related]
5. Persistent T cell-mediated immune responses against Omicron variants after the third COVID-19 mRNA vaccine dose.
Belik M; Liedes O; Vara S; Haveri A; Pöysti S; Kolehmainen P; Maljanen S; Huttunen M; Reinholm A; Lundberg R; Skön M; Österlund P; Melin M; Hänninen A; Hurme A; Ivaska L; Tähtinen PA; Lempainen J; Kakkola L; Jalkanen P; Julkunen I
Front Immunol; 2023; 14():1099246. PubMed ID: 36756112
[TBL] [Abstract][Full Text] [Related]
6. Neutralizing immunity against SARS-CoV-2 Omicron BA.1 by infection and vaccination.
Duan LJ; Jiang WG; Wang ZY; Yao L; Zhu KL; Meng QC; Wang BS; Li LB; Wang GL; Ma MJ
iScience; 2022 Sep; 25(9):104886. PubMed ID: 35966041
[TBL] [Abstract][Full Text] [Related]
7. BBIBP-CorV vaccination accelerates anti-viral antibody responses in heterologous Omicron infection: A retrospective observation study in Shanghai.
Bao Y; He L; Miao B; Zhong Z; Lu G; Bai Y; Liang Q; Ling Y; Ji P; Su B; Zhao GP; Wu H; Zhang W; Wang Y; Chen Y; Xu J
Vaccine; 2023 May; 41(20):3258-3265. PubMed ID: 37085449
[TBL] [Abstract][Full Text] [Related]
8. Antibody response against SARS-CoV-2 variants of concern in children infected with pre-Omicron variants: An observational cohort study.
Seery V; Raiden S; Russo C; Borda M; Herrera L; Uranga M; Varese A; Marcó Del Pont M; Chirino C; Erramuspe C; Álvarez LS; Lenoir M; Morales LD; Davenport C; Alarcón Flores A; Huespe Auchter S; Ruiz Y; Monsalvo L; Sastoque L; Gavazzi M; Mazzitelli I; Di Diego F; Longueira Y; Mazzitelli B; Sananez I; De Carli N; Biglione MM; Gómez Penedo JM; Ceballos A; Laufer N; Ferrero F; Geffner J; Arruvito L
EBioMedicine; 2022 Sep; 83():104230. PubMed ID: 35988465
[TBL] [Abstract][Full Text] [Related]
9. Single Ad26.COV2.S booster dose following two doses of BBIBP-CorV vaccine against SARS-CoV-2 infection in adults: Day 28 results of a phase 1/2 open-label trial.
Muangnoicharoen S; Wiangcharoen R; Nanthapisal S; Kamolratakul S; Lawpoolsri S; Jongkaewwattana A; Thitithanyanont A; Luvira V; Chinwangso P; Thanthamnu N; Chantratita N; Lim JK; Anh Wartel T; Excler JL; Ryser MF; Leong C; Mak TK; Pitisuttithum P
Vaccine; 2023 Jul; 41(32):4648-4657. PubMed ID: 37344265
[TBL] [Abstract][Full Text] [Related]
10. Effectiveness of BNT162b2 and CoronaVac COVID-19 vaccination against asymptomatic and symptomatic infection of SARS-CoV-2 omicron BA.2 in Hong Kong: a prospective cohort study.
Tsang NNY; So HC; Cowling BJ; Leung GM; Ip DKM
Lancet Infect Dis; 2023 Apr; 23(4):421-434. PubMed ID: 36521506
[TBL] [Abstract][Full Text] [Related]
11. Enhanced antibody responses in fully vaccinated individuals against pan-SARS-CoV-2 variants following Omicron breakthrough infection.
Jeong HW; Kim SM; Jung MK; Noh JY; Yoo JS; Kim EH; Kim YI; Yu K; Jang SG; Gil J; Casel MA; Rare R; Choi JH; Kim HS; Kim JH; Um J; Kim C; Kim Y; Chin BS; Jung S; Choi JY; Song KH; Kim YD; Park JS; Song JY; Shin EC; Choi YK
Cell Rep Med; 2022 Oct; 3(10):100764. PubMed ID: 36182684
[TBL] [Abstract][Full Text] [Related]
12. SARS-CoV-2 Omicron variant BA.2 neutralisation in sera of people with Comirnaty or CoronaVac vaccination, infection or breakthrough infection, Hong Kong, 2020 to 2022.
Cheng SM; Mok CKP; Chan KC; Ng SS; Lam BH; Luk LL; Ko FW; Chen C; Yiu K; Li JK; Chan KK; Tsang LC; Poon LL; Hui DS; Peiris M
Euro Surveill; 2022 May; 27(18):. PubMed ID: 35514306
[TBL] [Abstract][Full Text] [Related]
13. Effectiveness of COVID-19 vaccines against SARS-CoV-2 Omicron variants during two outbreaks from March to May 2022 in Quzhou, China.
Yin Z; Fang Q; Wen T; Zheng C; Fu C; Wang S; Li J; Gong X
Hum Vaccin Immunother; 2023 Dec; 19(1):2163813. PubMed ID: 36704960
[TBL] [Abstract][Full Text] [Related]
14. Omicron neutralizing antibody response following booster vaccination compared with breakthrough infection.
Curlin ME; Bates TA; Guzman G; Schoen D; McBride SK; Carpenter SD; Tafesse FG
Med; 2022 Dec; 3(12):827-837.e3. PubMed ID: 36198311
[TBL] [Abstract][Full Text] [Related]
15. Assessment of antibody responses against SARS-CoV-2 in unvaccinated individuals and vaccinees from Omicron-BA.2 infection in Zhaoqing, Guangdong Province, China.
Zhang H; Jiang Y; Tan H; Zou L; Zheng Z; Huang Y; Lin S; Su L; Yu J; Deng X; He J; Liu C; Shen C; Li B
Virol J; 2022 Nov; 19(1):197. PubMed ID: 36434614
[TBL] [Abstract][Full Text] [Related]
16. Detection of SARS-CoV-2 antibodies after confirmed Omicron BA.1 and presumed BA.4/5 infections using Abbott ARCHITECT and Panbio assays.
Boler M; Anderson M; Rodgers M; Parumoottil J; Olivo A; Harris B; Stec M; Gosha A; Behun D; Holzmayer V; Anderson A; Greenholt E; Fortney T; Almaraz E; Cloherty G; Landay A; Moy J
IJID Reg; 2023 Jun; 7():277-280. PubMed ID: 37234563
[TBL] [Abstract][Full Text] [Related]
17. Protection against symptomatic infection with delta (B.1.617.2) and omicron (B.1.1.529) BA.1 and BA.2 SARS-CoV-2 variants after previous infection and vaccination in adolescents in England, August, 2021-March, 2022: a national, observational, test-negative, case-control study.
Powell AA; Kirsebom F; Stowe J; Ramsay ME; Lopez-Bernal J; Andrews N; Ladhani SN
Lancet Infect Dis; 2023 Apr; 23(4):435-444. PubMed ID: 36436536
[TBL] [Abstract][Full Text] [Related]
18. Inactivated Vaccine-Induced SARS-CoV-2 Variant-Specific Immunity in Children.
Soto JA; Melo-González F; Gutierrez-Vera C; Schultz BM; Berríos-Rojas RV; Rivera-Pérez D; Piña-Iturbe A; Hoppe-Elsholz G; Duarte LF; Vázquez Y; Moreno-Tapia D; Ríos M; Palacios PA; Garcia-Betancourt R; Santibañez Á; Pacheco GA; Mendez C; Andrade CA; Silva PH; Diethelm-Varela B; Astudillo P; Calvo M; Cárdenas A; González M; Goldsack M; Gutiérrez V; Potin M; Schilling A; Tapia LI; Twele L; Villena R; Grifoni A; Sette A; Weiskopf D; Fasce RA; Fernández J; Mora J; Ramírez E; Gaete-Argel A; Acevedo ML; Valiente-Echeverría F; Soto-Rifo R; Retamal-Díaz A; Muñoz-Jofré N; ; Meng X; Xin Q; Alarcón-Bustamante E; González-Aramundiz JV; Le Corre N; Álvarez-Figueroa MJ; González PA; Abarca K; Perret C; Carreño LJ; Bueno SM; Kalergis AM
mBio; 2022 Dec; 13(6):e0131122. PubMed ID: 36383021
[TBL] [Abstract][Full Text] [Related]
19. Impact of Age and Severe Acute Respiratory Syndrome Coronavirus 2 Breakthrough Infection on Humoral Immune Responses After Three Doses of Coronavirus Disease 2019 mRNA Vaccine.
Mwimanzi F; Lapointe HR; Cheung PK; Sang Y; Yaseen F; Kalikawe R; Datwani S; Burns L; Young L; Leung V; Ennis S; Brumme CJ; Montaner JSG; Dong W; Prystajecky N; Lowe CF; DeMarco ML; Holmes DT; Simons J; Niikura M; Romney MG; Brumme ZL; Brockman MA
Open Forum Infect Dis; 2023 Mar; 10(3):ofad073. PubMed ID: 36910697
[TBL] [Abstract][Full Text] [Related]
20. Effectiveness of mRNA-1273, BNT162b2, and BBIBP-CorV vaccines against infection and mortality in children in Argentina, during predominance of delta and omicron covid-19 variants: test negative, case-control study.
Castelli JM; Rearte A; Olszevicki S; Voto C; Del Valle Juarez M; Pesce M; Iovane AN; Paz M; Chaparro ME; Buyayisqui MP; Markiewicz MB; Landoni M; Giovacchini CM; Vizzotti C
BMJ; 2022 Nov; 379():e073070. PubMed ID: 36450402
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
